Analysis of bone mineral density in urolithiasis patients

International Journal of Urology

Volumn 12, Issue 4, 2005, Pages 335-339

  Tsuji, Hidenori ^a   Umekawa, Tohru ^a   Kurita, Takashi ^a   Uemura, Hirotsugu ^a   Iguchi, Masanori ^b   Kin, Kokai ^b   Kushida, Kazuhiro ^b  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone mineral density; Menopause; Osteoporosis; Percent age matched score; Urolithiasis

Indexed keywords

ADULT; AGED; ARTICLE; BONE DENSITY; CALCIUM EXCRETION; CALCIUM INTAKE; CALCIUM METABOLISM; CALCIUM URINE LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCALCIURIA; JUVENILE; LUMBAR VERTEBRA; MALE; MEDICAL EXAMINATION; MENOPAUSE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; STONE ANALYSIS; UROLITHIASIS;

ADULT; AGE FACTORS; BONE DENSITY; CALCIUM; DENSITOMETRY, X-RAY; FEMALE; HUMANS; INCIDENCE; KIDNEY CALCULI; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS;

EID: 22044445850     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2005.01049.x     Document Type: Article

References (29)

1. Embon OM, Rose GA, Rosenbaum T. Chronic dehydration stone disease. Br. J. Urol. 1990; 66: 357-62.
2. Hodgkinson A, Pyrah LN. The urinary excretion of calcium and inorganic phosphate in 344 patients with calcium of renal origin. Br. J. Surg. 1958; 46: 10-18.
3. Coe FL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria or no metabolic disorders. Ann. Intern. Med. 1997; 87: 404-10.
4. Pietschmann F, Breslau NA, Pak CYC. Reduced vertebral bone density in hypercalciuric urolithiasis. J. Bone Miner. Res. 1992; 7: 1383-8.
5. Bataille P, Achard JM, Fournier A et al. Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int. 1991; 39: 1193-205.
6. Iguchi M, Takamura T, Umekawa T, Kurita T, Kohri K. Inhibitory effects of female sex hormones on urinary stone formation in rats. Kidney Int. 1999; 56: 479-85.
7. Kohri K, Kodama M, Ishikawa Y et al. Relationship between metabolic acidosis and calcium phosphate urinary stone formation in women. Int. Urol. Nephrol. 1991; 23: 307-316.
8. Yoshida O, Okada Y. Epidemiology of urolithiasis in Japan: a chronological and geographical study. Urol. Int. 1990; 45: 104-111.
9. Zanchetta JR, Rodriguez G, Negri AL, del Valle E, Spivacow FR. Bone mineral density in patients with hypercalciuric nephrolithiasis. Nephron 1996; 73: 557-60.
10. Riggs BL, Melton LJ III. Involutional osteoporosis. N. Engl. J. Med. 1986; 314: 1676-86.
11. Genant HK, Baylink DJ, Gallagher JC. Estrogens in the prevention of osteoporosis in postmenopausal women. Am. J. Obstet. Gynecol. 1987; 69: 929-32.
12. Gallagher JC. Role of estrogens in the management of postmenopausal bone loss. Rheum. Dis. Clin. North Am. 2001; 27: 143-62.
13. Kameda T, Miyazawa K, Mori Y et al. Vitamin K2 inhibits osteoclastic bone resorption by inducing osteoclast apoptosis. Biochem. Biophys. Res. Commun. 1996; 220: 515-19.
14. Hara K, Akiyama Y, Nakamura T, Murota S, Morita I. The inhibitory effect of vitamin K2 (menatetrenone) on bone resorption may be related to its side chain. Bone 1995; 16: 179-84.
15. Zittermann A. Effects of vitamin K on calcium and bone metabolism. Curr. Opin. Clin. Nutr. Metab. Care 2001; 4: 483-7.
16. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J. Bone Miner. Res. 2000; 15: 515-21.
17. Heilberg IP, Martini LA, Teixeira SH et al. Effect of etidronate treatment on bone mass of male nephrolithasis patients with ideopathic hypercalciuria and osteopenia. Nephron 1998; 79: 430-37.
18. Ohkawa M, Tokunaga S, Nakashima T, Orito M, Hisazumi H. Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. Br. J. Urol. 1992; 69: 571-6.
19. Stefikova K, Spustova V, Dzurik R. Acute effect of hydrochlorothiazide on renal calcium and magnesium handling in postmenopausal women. Physiol. Res. 1999; 48: 327-30.
20. Reusz GS, Dobos M, Vasarhelyi B et al. Sodium transport and bone mineral density in hypercalciuria with thiazide treatment. Pediatr. Nephrol. 1998; 12: 30-34.
21. Adams JS, Song CF, Kantorovich V. Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Ann. Intern. Med. 1999; 130: 658-60.
22. Blacklock NJ. Epidemiology or urolithiasis. In: Williams DJ, Chisholm GD (eds). Scientific Foundations of Urology Vol. 1. William Heine mann Medical Books Ltd., London, 1976; 235-43.
23. Iguchi M, Kataoka K, Kohri K, Yachiku S, Kurita T. Nutritional risk factors in calcium stone disease in Japan. Urol. Int. 1984; 39: 32-5.
24. Recker RR, Davies KM, Hinders SM, Heaney RP, Stegman MR, Kimmel DB. Bone gain in young adult women. JAMA 1992; 268: 2403-408.
25. Nomura K, Ito H, Masai M. Reduction of urinary stone recurrence by dietary counceling. J. Endourol. 1995; 9: 305-312.
26. Curhan GC, Willett WC, Rimm EB. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N. Engl. J. Med. 1993; 328: 833-8.
27. Heller HJ. The role of calcium in the prevention of kidney stones. J. Am. Coll. Nutr. 1999; 18: 373-8.
28. Christiansen C, Christennsen MS, Transbol I. Bone mass after withdrawal of estrogen replacement. Lancet 1981; 1: 1053-4.
29. Domrongkitchaiporn S, Ongphiphadhanakul B, Stitchantrakul W et al. Risk of calcium oxalate nephrolithasis in postmenoposal women supplemented with calcium or combined calcium and estrogen. Maturitas 2002; 41: 149-56.